Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-05-15

Clinical Trial Update: A Study of MLN0264 in Patients With Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of MLN0264 in pancreatic adenocarcinoma was terminated, with results posted in May 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MLN0264

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Pancreatic Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2017-05-15